Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Internal Medicine Journal
|
December 11, 2020
Trends in practice: attitudes and challenges in the diagnosis, treatment and management of HIV infection in Australia
Don E Smith, Ian J Woolley, Darren B Russell, et al.
International Journal of Transgender Health
|
October 28, 2024
"Ever since I knew I was trans I knew I wanted hormone therapy": a qualitative exploration into the journey of Australian trans individuals accessing feminizing gender-affirming hormone therapy
James A Fowler, Sarah Warzywoda, Nia Franks, et al.
Journal of Homosexuality
|
March 8, 2023
Highs, Lows, and Hormones: A Qualitative Metasynthesis of Transgender Individuals' Experiences Undergoing Gender-Affirming Hormone Therapy
James A Fowler, Sarah Warzywoda, Nia Franks, et al.
Culture, Health & Sexuality
|
June 3, 2024
One person, many changes: a socioecological qualitative analysis of the experiences of transfeminine individuals undergoing feminising gender-affirming hormone therapy
James A Fowler, Sarah Warzywoda, Mera Reyment, et al.
International Journal of Transgender Health
|
November 3, 2025
How low can you go? Titrating the lowest effective dose of cyproterone acetate for transgender and gender diverse people who request feminizing hormones
Sarah Warzywoda, James A Fowler, Penny Wood, et al.
Australian Journal of General Practice
|
April 6, 2023
Impact of harm reduction practice on the use of non-prescribed performance and image-enhancing drugs: The PUSH! Audit
Beng Eu, Joshua Dawe, Matthew Dunn, et al.
International Journal of Transgender Health
|
October 28, 2024
Monitoring and reporting of adverse effects of testosterone prescribing for gender affirmation at general practice clinics - Data from the PUSH! Audit
Beng Eu, Joshua Dawe, Matthew Dunn, et al.
Open Forum Infectious Diseases
|
July 17, 2024
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis
Stefan Scholten, Pedro Cahn, Joaquín Portilla, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 12, 2024
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196
Stéphane De Wit, Fabrice Bonnet, Olayemi Osiyemi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 26, 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Internal Medicine Journal
|
December 11, 2020
Trends in practice: attitudes and challenges in the diagnosis, treatment and management of HIV infection in Australia
Don E Smith, Ian J Woolley, Darren B Russell, et al.
International Journal of Transgender Health
|
October 28, 2024
"Ever since I knew I was trans I knew I wanted hormone therapy": a qualitative exploration into the journey of Australian trans individuals accessing feminizing gender-affirming hormone therapy
James A Fowler, Sarah Warzywoda, Nia Franks, et al.
Journal of Homosexuality
|
March 8, 2023
Highs, Lows, and Hormones: A Qualitative Metasynthesis of Transgender Individuals' Experiences Undergoing Gender-Affirming Hormone Therapy
James A Fowler, Sarah Warzywoda, Nia Franks, et al.
Culture, Health & Sexuality
|
June 3, 2024
One person, many changes: a socioecological qualitative analysis of the experiences of transfeminine individuals undergoing feminising gender-affirming hormone therapy
James A Fowler, Sarah Warzywoda, Mera Reyment, et al.
International Journal of Transgender Health
|
November 3, 2025
How low can you go? Titrating the lowest effective dose of cyproterone acetate for transgender and gender diverse people who request feminizing hormones
Sarah Warzywoda, James A Fowler, Penny Wood, et al.
Australian Journal of General Practice
|
April 6, 2023
Impact of harm reduction practice on the use of non-prescribed performance and image-enhancing drugs: The PUSH! Audit
Beng Eu, Joshua Dawe, Matthew Dunn, et al.
International Journal of Transgender Health
|
October 28, 2024
Monitoring and reporting of adverse effects of testosterone prescribing for gender affirmation at general practice clinics - Data from the PUSH! Audit
Beng Eu, Joshua Dawe, Matthew Dunn, et al.
Open Forum Infectious Diseases
|
July 17, 2024
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis
Stefan Scholten, Pedro Cahn, Joaquín Portilla, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 12, 2024
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196
Stéphane De Wit, Fabrice Bonnet, Olayemi Osiyemi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 26, 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana, et al.
Page
of 2